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Background: Advances in the diagnosis and treatment of urea cycle disorders (UCDs) have led to a higher survival
rate. The purpose of this study is to describe the characteristics of patients with urea cycle disorders in Spain.
Methods: Observational, cross-sectional and multicenter study. Clinical, biochemical and genetic data were collected
from patients with UCDs, treated in the metabolic diseases centers in Spain between February 2012 and February 2013,
covering the entire Spanish population. Heterozygous mothers of patients with OTC deficiency were only included if
they were on treatment due to being symptomatic or having biochemistry abnormalities.
Results: 104 patients from 98 families were included. Ornithine transcarbamylase deficiency was the most
frequent condition (64.4%) (61.2% female) followed by type 1 citrullinemia (21.1%) and argininosuccinic aciduria
(9.6%). Only 13 patients (12.5%) were diagnosed in a pre-symptomatic state. 63% of the cases presented with type
intoxication encephalopathy. The median ammonia level at onset was 298 μmol/L (169-615). The genotype of 75
patients is known, with 18 new mutations having been described. During the data collection period four patients
died, three of them in the early days of life. The median current age is 9.96 years (5.29-18), with 25 patients over
18 years of age. Anthropometric data, expressed as median and z-score for the Spanish population is shown.
52.5% of the cases present neurological sequelae, which have been linked to the type of disease, neonatal onset,
hepatic failure at diagnosis and ammonia values at diagnosis. 93 patients are following a protein restrictive diet,
0.84 g/kg/day (0.67-1.10), 50 are receiving essential amino acid supplements, 0.25 g/kg/day (0.20-0.45), 58 arginine,
156 mg/kg/day (109-305) and 45 citrulline, 150 mg/kg/day (105-199). 65 patients are being treated with drugs:
4 with sodium benzoate, 50 with sodium phenylbutyrate, 10 with both drugs and 1 with carglumic acid.
Conclusions: Studies like this make it possible to analyze the frequency, natural history and clinical practices in
the area of rare diseases, with the purpose of knowing the needs of the patients and thus planning their care.
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The urea cycle is the final common pathway for the excre-
tion of waste nitrogen as well as arginine synthesis [1,2].
Urea cycle disorders (UCDs) are caused by a deficiency of
one of the six enzymes in this cycle. Three of the enzymes
are mitochondrial, N-acetylglutamate synthase (NAGS),
carbamoylphosphate synthetase 1 (CPS1), and ornithine
transcarbamylase (OTC), and the other three are cytoplas-
mic, argininosuccinate synthetase (ASS), argininosucci-
nate lyase (ASL) and arginase 1 (ARG1). As the metabolic
steps take place in two different cellular compartments,
two transporters are also necessary: the ornithine/citrul-
line antiporter ORNT1, deficiency of which causes
hyperornithinemia-hyperammonemia-homocitrullinuria
syndrome and the glutamate/aspartate antiporter CITRIN,
deficiency of which gives rise to type 2 citrullinemia. All
these deficiencies are inherited in an autosomal recessive
manner, except for OTC deficiency which is inherited in
an X-linked recessive manner.
The incidence of UCDs varies between 1:22.179-
1:53.717 newborns [3-7] although it could be higher, con-
sidering that not all the cases are detected by expanded
newborn screening (NBS) and many can be undiagnosed
cases with a fatal outcome.
The clinical presentation is variable; the onset of se-
vere forms usually occurs during the neonatal period
and it is characterized by food refusal, vomiting, leth-
argy, polypnea, and rapid progression to coma and mul-
tiorgan failure [8]. There is high mortality among this
type of patients and those who survive experience fre-
quent subsequent decompensation and bad neurological
prognosis [9]. The onset of mild forms can occur at any
age with hyperammonemic episodes triggered during
metabolic stress (infections, vomiting, surgery, etc.) or
with more insidious symptoms such as failure to thrive,
liver disease, developmental delay, behavioral disorders
or psychiatric symptoms [10]. The biochemical data that
helps making the diagnosis is hyperammonemia together
with the amino acid and organic acid pattern. The diag-
nosis is confirmed through an enzymatic and/or genetic
study. Treatment is primarily based on a low protein
diet, essential amino acids (EAA) supplements, arginine
and/or citrulline, and the use of nitrogen scavenging
drugs such as sodium benzoate (BZ) or sodium phenyl-
butyrate (PBA) [11]. No protein restriction is necessary
when treating NAGS deficiency with carglumic acid.
Diagnostic and treatment advances over recent years,
including newborn screening (NBS) for some of the con-
ditions [12,13], acute hyperammonemia treatment guide-
lines [11,14,15], extracorporeal detoxification [16,17],
nutritional therapy [18], nitrogen scavenging drugs [19],
liver transplantation [20,21], etc., have decreased the mor-
tality rates, and many patients reach adulthood. However,
neurological sequelae are still prominent. Since these arerare conditions and the number of patients in each center
is low, it is necessary to conduct multicenter studies to
understand the new natural history of the disease. A regis-
try of patients has been started recently in the USA [22]
and another one in Europe [23]. In Spain there was no in-
formation on patients with these diseases, so the Spanish
Association of Inborn Errors of Metabolism (AECOM)
has promoted this observational, cross-sectional and mul-
ticenter study that aims to find out the number of patients
with urea cycle disorders, as well as their clinical and
laboratory characteristics, in order to plan their care.
Methods
Data used in the analysis were collected at enrolment in a
national registry of patients with UCDs. The study was
carried out by the Spanish urea cycle disorders study
group, members of the AECOM. All inherited metabolic
diseases (IMD) centers in Spain, covering the entire popu-
lation of the country, answered a questionnaire regarding
clinical and analytical information at diagnosis and at last
visit of patients with UCDs alive during the study period.
The inclusion criteria were:
1. Data collection between February 2012 and February
2013, 12 months.
2. Live patients at any time during the study period,
even if the patient died later on.
3. Urea cycle disorder diagnosis due to a deficiency of
any of the six enzymes of the cycle.
4. Heterozygous mothers of patients with OTC
deficiency were only included if they were on
treatment due to being symptomatic or having
biochemistry anomalies.
Informed consent was obtained for their inclusion in
the registry and for anonymous publication of the data.
The data were anonymized before their assessment and
statistical analysis. The registry was approved by the
Ethics Committee of the 12 de Octubre Hospital
(Madrid, Spain).
The data obtained at diagnosis was: type of disorder,
gender, age at onset of symptoms and age at diagnosis,
ethnic origin, UCD family history or family consanguinity,
presentation (neonatal, late or pre-symptomatic), diagnos-
tic method (biochemical, enzymatic, genetic), clinical
symptoms, biochemical parameters and molecular study.
Biochemical and molecular studies were performed over a
long period of time in different laboratories using diverse
methods, some of them previously published [24-28]. In
none of the cases the molecular study was done by next-
generation sequencing (NGS).
Data obtained on the last visit during the study period
was: age, anthropometric data (weight, height and head
circumference), liver damage (hypertransaminasemia,
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velopmental delay, mental retardation, learning disorder,
behavior disorders, motor disorders and epilepsy), bio-
chemical parameters, dietary treatment (total protein,
energy, essential amino acids, L-arginine, L-citrulline)
and pharmacological treatment. Anthropometric param-
eters were collected by standard procedures in each
center and expressed as z-scores, using published Spanish
population values as a reference [29].
Statistical methods: data are expressed as mean and
standard deviation (SD) or median and interquartile range
(IQR) for quantitative variables and percentages for
qualitative variables. The level of statistical significance
was obtained using Chi-square or Fisher’s Exact Test
for qualitative variables and Student’s T-test or the




A total of 104 patients from 98 different families were
included, with the following diagnosis: 67 OTC defi-
ciency (64.4%), 22 ASS deficiency (type 1 citrullinemia)
(21.1%), 10 ASL deficiency (argininosuccinic aciduria)
(9.6%), 2 CPS1 deficiency (1.92%), 2 ARG1 deficiency
(1.92%) and 1 NAGS deficiency (0.96%). Some of the
patients have been previously published [24-28,30].
Almost half of the patients (47%, 49 cases) were male
and 53% (55) female. From the 67 cases with OTC defi-
ciency, 38.8% (26) were male and 61.2% (41) female
(Table 1). Other relatives were affected in 20.4% of the
cases and there was family consanguinity in 5.9% of the
cases. Most patients were European (90.4%, 94 subjects),
with a small number of patients from other geographical
origins: 5.7% (6) from Morocco, and 3.8% (4) from Latin
America.
During the study time 11 new cases were diagnosed, 6
of them were born in that period (3 with neonatal onsetTable 1 Description of the series
Disease Number (%) Gender*
Male Female
OTCD 67 (64.4) 26 (38.8) 41 (61.2)
ASSD 22 (21.1) 13 (59) 9 (61)
ASLD 10 (9.61) 6 (60) 4 (40)
CPS1D 2 (1.92) 1 (50) 1 (50)
ARG1D 2 (1.92) 2 (100) 0
NAGSD 1 (0.96) 1 (100) 0
Total 104 (100) (98 families) 49 (47.1) 55 (52.9)
OTCD: ornithine transcarbamylase deficiency. ASSD: argininosuccinate synthetase defic
synthetase 1 deficiency; ARG1D: arginase 1 deficiency; NAGSD: N-acetylglutamate synt
*Number of cases (%).and 3 diagnosed by NBS) and 5 had been born in previ-
ous years.
The median age at onset, in patients with clinical symp-
toms, was 12.7 months (0.2-28) and the median age at
diagnosis was 16.3 months (0.2-43.2). The median age of
asymptomatic patients at diagnosis was 0.46 months
(0.17-53).
During the first year 44.2% of the cases (46) were diag-
nosed, between 1 year and 6 years, 39.4% (41), between
6 and 12 years 11.5% (12), between 12 and 18 years 1.9%
(2) and the remaining 2.8% (3) were diagnosed in
adulthood.
Symptoms and biochemical data at diagnosis
Symptoms began during the neonatal period in 25.9% of
the cases (27), 61.5% (64) had a late onset and only
12.5% (13) were asymptomatic at diagnosis. Therefore,
87.5% of the patients (91) were index-patients diagnosed
due to symptoms. Neurological deterioration “intoxica-
tion type” was present in 63% of the cases. The rest of
the symptomatic patients presented other neurological
and/or digestive symptoms at onset. Psychiatric symp-
toms, such as psychosis in the 12 year old NAGSD
patient [30],were observed in 1.9% of the patients.
Of the 13 cases diagnosed in the pre-symptomatic
state, 5 were detected through NBS (3 ASSD, 1 ASLD
and 1 ARG1D), one was a prenatal diagnosis (ASL
deficiency), and the remaining 7 were diagnosed through
family history (6 OTCD and 1 ASSD).
Figure 1 shows the type of presentation according to
the disorder. 63.6% of the patients with type 1 citrulline-
mia had neonatal onset, while in OTC and ASL deficien-
cies a late onset was more frequent (77.6% and 60%,
respectively). Among patients with OTC deficiency, 9
had neonatal onset (7 males), 52 had late onset (15
males) and 6 were asymptomatic at diagnosis (4 males).
4 of the asymptomatic patients were children (3 males, 1
female); another one was a heterozygous mother treatedPresentation*
Symptomatic Asymptomatic
Neonatal Late
9 (13.4) 7 males 52(77.6) 15 males 6 (9) 4 males
14 (63.6) 4 (18.2) 4 (18.2)
2 (20) 6 (60) 2 (20)
1(50) 1 (50)
1 (50) 1 (50)
- 1 (100) -
27 (26) 64 (61.5) 13 (12.5)
iency; ASLD: argininosuccinate lyase deficiency; CPS1D: carbamoylphosphate
hase deficiency.
Figure 1 The table under the figure shows the number of cases with neonatal, late or asymptomatic presentation in each disease.
Most of the ASS deficient patients had neonatal onset. Among asymptomatic patients with OTC deficiency only one was a heterozygous mother
included and treated because of biochemical abnormalities.
Table 2 Biochemical data at diagnosis (excluding
asymptomatic patients) and at last visit (all patients)






Ammonia (μmol/L) 298 (169-615) 33 (27-42) 10-55 (80**)
Glutamine (μmol/L) 1124 (859-1546) 716 (545-908) 350-650
Prothrombin
activity (%)
60 (32.6-82) 91 (85-100) 75-130
ALT (IU/L) 76 (38-159) 24 (16-34) 5-39
AST (IU/L) 53.5 (36.7-161) 27.5 (19-37.2) 5-37
Bilirrubin (mg/dL) 0.60 (0.43-3.77) 0.53 (0.30-0.80) 0.20-1.10
Albumin (g/L) 3.79 (3-4.41) 4.30 (3.90-4.50) 3.80-5.40
pH 7.43 (7.36-7.46) - 7.35-7.45
Bicarbonate (mmol/L) 21 (19-24) - 23-27
*Median and interquartile range (IQR); **Normal values in newborns.
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at diagnosis and the last one was an adult man with
biochemical abnormalities, who was also treated in order
to prevent an acute hyperammonemic encephalopathy.
With respect to ARG1 deficiency, a very rare disease,
there are two patients in our series. The first one is a male
diagnosed through NBS with arginine levels of 112 μmol/
L at 48 h of age (reference range: 0.2- 49.54). Ammonia
and glutamine were normal (50 and 350 μmol/L respect-
ively) and the diagnosis was confirmed by enzymatic activ-
ity in red cells. The second one is a male who presented at
2 days of age with respiratory distress, food refusal and
seizures. Ammonia level was 164 μmol/L, glutamine
1105 μmol/L and arginine 590 μmol/L. He was diagnosed
by enzymatic study in red cells.
Median ammonia level at onset in symptomatic pa-
tients was 298 μmol/L (169-615) and median glutamine
level was 1124 μmol/L (859-1546). Three cases with
argininosuccinic aciduria and 1 case with OTC defi-
ciency showed normal values of ammonia and glutamine
at onset. 17 patients had biochemical parameters con-
sistent with acute liver failure. Other biochemical data
are shown in Table 2. Blood levels of citrulline and
arginine in each type of disease are shown in Table 3.
The diagnosis was confirmed through enzymatic activ-
ity in 40.4% (42) and/or through molecular study in
79.8% (83) of the cases, although we only have available
the genotype of 72.1% (75) of the subjects. In 12 (11
symptomatic, 1 asymptomatic) OTC female patients,despite their mosaic nature, deficient OTC activity was
supported in jejunal biopsy.
Molecular genetic data
The genetic study was available in 79 patients (56 OTC,
14 ASS, 7 ASL, 1 CPS and 1 NAGS). The genotype of
72.1% of the patients (75) is known. Eight OTC, 2 ASS,
5 ASL, 1CPS and 2 NAGS mutations have not been
previously reported.
Table 4 lists the 39 different mutations of the 52 pa-
tients (48 families) with OTC deficiency. In 4 OTC defi-
cient patients mutations were not found. Therefore the
Table 3 Levels of specific urea cycle amino acids at
diagnosis for the different diseases
Type of UCD Amino acid*
Citrulline (μmol/L)
(NV: 26 ± 8)
Arginine (μmol/L)
(NV: 64 ± 24)
NAGSD, CPS1D, OTCD 10 (7-16) 39 (20-59)
ASSD 1654 (984-2400) 31 (17-41)
ASLD 173 (103-256) 36 (24-81)
ARG1D 21 (20.5- 21.5) 351 (231-470)
*Median and interquartile range (IQR).
NV: normal values.
NAGSD: N-acetylglutamate synthase deficiency; CPS1D: Carbamoylphosphate
synthetase 1 deficiency; OTCD: Ornithine transcarbamylase deficiency; ASSD:
Argininosuccinate synthetase deficiency; ASLD: Argininosuccinate lyase
deficiency; ARG1D: Arginase 1deficiency.
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Table 4 includes information on the gender, time and se-
verity at onset and neurological situation at last visit.
References of previously reported cases are indicated
next to the number of the patient [24-27]. The most fre-
quent mutation was p.Arg129His which was identified in
5 patients (3 females) from 4 families, all of them with
good neurologic outcome. On the other hand, the two
patients with a deletion of the whole OTC gene are very
symptomatic. For other frequent mutations, such as p.
Arg40His or p.Gly195Arg, neurological outcome is re-
lated more to the time and severity at onset rather than
the mutation itself, with poorer outcome of index-cases
than asymptomatic siblings diagnosed through family
history (Table 4).
We include eight new mutations, not previously re-
ported in the public database HGMD® [31]: p.Thr343Arg,
p.Glu273del, p.Thr93Ileu, p.Lys88Thr, c.298 + 1G > C
(IVS3 + 1G > C), p.Ileu85Ser, p.Phe48Leufs*16, andp.
Lys210Asnfs*20. The first six mutations were identified
in 2 males and 4 females with late onset and without
neurological damage at their last visit. The mutation p.
Lys210Asnfs*20 was found in a girl that suffered acute
encephalopathy at 6 months of age and has develop-
mental delay in the outcome. Finally, the p.Phe48-
Leufs*16 mutation was identified in a case with onset
two days after birth with ammonia levels of 4584 μmol/
L who only survived a few hours.
Table 5 includes the information of the patients with
ASS, ASL, CPS and NAGS deficiency . We have no mo-
lecular genetic data for any of the cases with argininemia.
Regarding type 1 citrullinemia, twelve different muta-
tions in the ASS1 gene were identified in 14 subjects.
The most frequent mutation, p.Gly390Arg, was identi-
fied in homozygosis in two patients with neonatal onset
and poor outcome. The 3 patients with mutation p.
Arg86Cys in homozygosis, diagnosed through NBS, late
onset hepatic failure or neurological symptoms, had no
neurological sequelae in their last visit. Two newmutations of the ASS1 gene have been identified: p.
Met186Arg was identified in homozygosis in one patient
of Romanian origin who presented acute encephalopathy
“intoxication type” and multiorgan failure in the neonatal
period. The other new mutation, p.Thr91Ala, was identi-
fied as heterozygous in a case diagnosed by NBS and who
remains asymptomatic to date.
Nine mutations in the ASL gene were identified in
seven patients (six families) with argininosuccinic acid-
uria, five of which have not been previously described: p.
Tyr45Asn, p.Gly316Glu, p.Pro208Arg, p.Gly301Arg and
p.Arg456Gln. All these mutations were found in patients
with late onset neurological symptoms, many times
without hyperammonemia, except for the p.Arg456Gln
mutation which was identified in a patient diagnosed by
NBS who remains asymptomatic at 4 years of age.
Current situation, data at last visit
Demographic data
During the 12-month data collection period four pa-
tients died, three in the neonatal period (2 OTCD males
and 1 ASSD) and one at the age of 9 (CPS1D). Thus, in
February of 2013 there were 100 patients registered with
UCDs in Spain.
The median age at last visit was 9.96 years (5.29-18).
25% of the patients were over 18 years, 16% were be-
tween 12 and 18 years, 33% were between 6-12 years,
22% were between 1-6 year and only 4% of them were
under the age of one year.
Anthropometric data
Table 6 shows the weight, height, and head circumfer-
ence for the different age groups at last visit and the
BMI for the adult group. The Z-score, calculated accord-
ing to the tables by Hernández et al. [29] for the Spanish
population, are also indicated. The z-score of weight was
below -2SD in 4.3% (4/92) of the patients, the z-score of
height was below -2SD in 13% (12/89) of the patients
and the z-score of head circumference was below -2SD
in 20% (5/20) of the patients.
Biochemical data
Table 2 shows some biochemical data at last visit, which
are within normal values, except for a slight increase in
glutamine.
Outcome
Neurological sequelae were seen in 52.5% (53) of the pa-
tients. Learning disorders in 50, developmental delay in
33, behavior disorders in 24, epilepsy in 15, motor disor-
ders in 14, and psychiatric disorders in 6. Brain magnetic
resonance imaging was performed in 46 patients, 22 of
which were normal. Neuropsychological assessment was
carried out in 26 patients (13 WISC-IV, 5 McCarthy, 4
Table 4 Mutations identified in 52 patients (48 families) with OTC deficiency
Patient n°/gender/[reference] Nucleotide Protein Onset Neurologic damage Alive
4 M c.1028C > G* p.Thr343Arg* Late No Yes
5 F c.663 + 2 T > C (IV6 + 2 T > C) Late Yes Yes
7 F c.533C > T p.Thr178Met Late No Yes
8 M c.421C > T p.Arg141Term Late No Yes
10 F c.533C > T p.Thr178Met Late Yes Yes
11 F c.914C > G p.Pro305Arg Late No Yes
12 M c.604C > T p.His202Tyr Late No Yes
13 F [27] c.287C > T p.Ser96Phe Late No Yes
14 F del814-816GAG* p.Glu273del* Late No Yes
16 F c.386 + 1G > A (IVS4 + 1G > A) Late Yes Yes
20 M c.365A > G p.Gln122Gly Late Yes Yes
21 M c.119G > A p.Arg40His A, FH No Yes
22 M c.264A > T p.Lys88Asn Late No Yes
25 M c.119G > A p.Arg40His Late No Yes
27 F c.67C > T p.Arg23Term Late Yes Yes
32 F [24] c.386G > A p.Arg129His Late No Yes
33 F [25] c.205C > T p.Gln69Term Late Yes Yes
36 F [25] delOTC gene >1.6 Mb Late Yes Yes
37 F c.583G > A p.Gly195Arg A, FH No Yes
38 F c.386G > A p.Arg129His Late No Yes
40 M [27] c.386 + 5G > A (IVS4 + 5G > A) Neonatal No Yes
45 F c.278C > T* p.Thr93Ileu* Late No Yes
48 M [24] c.386G > A p.Arg129His Neonatal No Yes
49 M c.86C > T p.Ala209Val Late Yes Yes
50 F c.476 T > C p.Ile159Thr Late Yes Yes
51 M [24] c.386G > A p.Arg129His Late No Yes
52 F [25] c.514A > T p.Ile172Phe Late No Yes
53 M c.829C > T p.Arg277Trp Late No Yes
54 M [26] c.571C > T p.Leu191Phe Late Yes Yes
55 M c.622G > A p.Ala208Thr Late Yes Yes
56 M c.263A > C* p.Lys88Thr* Late No Yes
59 M c.622G > A p.Ala208Thr A, FH No Yes
60 F c.298 + 1G > C (IVS3 + 1G > C)* Late No Yes
68 F c.1018C > T p.Ser340Pro Late Yes Yes
69 F [26] c.1022C > T p.Leu341Pro Late Yes Yes
72 F c.482A > G p.Asn161Asp Late No Yes
73 M c.144delT* p.Phe48Leufs*16* Neonatal - No
74 F c.254 T > G* p.Ileu85Ser* Late No Yes
75 F c.583G > A p.Gly195Arg A, FH No Yes
76 M c.119G > A p.Arg40His A, FH No Yes
77 M c.119G > A p.Arg40His Late Yes Yes
79 F c.154G > A p.Glu52Lys Late Yes Yes
80 F c.583G > A p.Gly195Arg Late Yes Yes
82 M c.622G > A p.Ala208Thr Late Yes Yes
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Table 4 Mutations identified in 52 patients (48 families) with OTC deficiency (Continued)
83 M c.932 T > A p.Val311Glu Neonatal No Yes
88 F c.605A > T p.His202Leu Late No Yes
91 F c.386 + 2 T > C (IVS4 + 2 T > C) Late No Yes
94 F c.630delA* p.Lys210Asnfs*20* Late Yes Yes
95 F delOTC gene >1.6 Mb Late Yes Yes
97 M c.958C > T p.Arg320Term Neonatal - No
100 F c.386G > A p.Arg129His Late No Yes
103 F [27] c.211G > T p.Gly71Term Late Yes Yes
In bold: *mutations not published in the public database HGMD [31].
F: female; M: male.
A: asymptomatic; FH: family history.
Cases 21 and 25, 32 and 51, 37 and 75, 76 and 77 are relatives.
[24-27]: references of primary publications where these patients and their mutations were published.
Table 5 Mutations identified in patients with ASS, ASL, CPS1 and NAGS deficiencies
Patient n°/
[reference]
Gene Nucleotide Protein Onset Neurologic
damage
1 ASS c.256C > T / c.256C > T p.Arg86Cys / p.Arg86Cys Late No
3 ASS c.206 T > C / c.206 T > C p.Val69Ala / p.Val69Ala Neonatal Yes
18 ASS c.557 T > G / c.557 T > G* p.Met186Arg / p.Met186Arg* Neonatal Yes
24 ASS c.970G > A / c.970G > A p.Gly324Ser / p.Gly324Ser Late No
41 ASS c.971G > T / c.1168G > A p.Gly324Val / p.Gly390Arg Neonatal Yes
46 ASS c.1168G > A /c.1168G > A p.Gly390Arg / p.Gly390Arg Neonatal Yes
66 [28] ASS c.350G > A / c.1168G > A p.Gly117Asp / p.Gly390Arg Late Yes
84 ASS c.970G > A / c.271A > G* p.Gly324Ser / p.Thr91Ala* A, NBS No
85 ASS c.256C > T / c.256C > T p.Arg86Cys / p.Arg86Cys A, NBS No
86 ASS c.256C > T / c.256C > T p.Arg86Cys / p.Arg86Cys Late No
96D ASS c.1168G > A /c.1168G > A p.Gly390Arg / p.Gly390Arg Neonatal -
98 [28] ASS c.323G > T + c.356C > T / NF p.Arg108Leu + p.Thr119Ile / NF Neonatal Yes
99 ASS c.892delG / c.1168G > A p.Glu298Argfs*/ p.Gly390Arg Neonatal Yes
101 ASS c.919C > T / NF p.Arg307Cys / NF A, NBS No
9 ASL c.133 T > A* / c.947G > A* p.Tyr45Asn* / p.Gly316Glu* Late Yes
29 ASL c.623C > G / c.623C > G* p.Pro208Arg / p.Pro208Arg* Late Yes
30 ASL c.623C > G / c.623C > G p.Pro208Arg / p.Pro208Arg Late Yes
39 ASL c.338G > A / c.338G > A p.Arg113Gln /p.Arg113Gln A, Prenatal Yes
47 ASL c.532G > A /c.901G > A* p.Val178Met / p.Gly301Arg* Late Yes
71 ASL c.1143 + 1G > T / c.1143 + 1G > T - Neonatal Yes
81 ASL c.1135C > T/c.1367G > A* p.Arg379Cys / p.Arg456Gln* A, NBS No
19 CPS1 c.2549G > T*/ NF p.Arg850Leu* / NF Late Yes
93 [30] NAGS c.499A > G* / c.916-2A > G* p.Met167Val */ Late No
In bold: *Mutations not published in the public database HGMD [31].
A: asymptomatic; NBS: newborn screening; D: Dead in the neonatal period; NF: not found.
Patients 29 and 30 are siblings.
[28,30]: references of primary publications where these patients were published.
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Table 6 Anthropometric data according to age group
N = 96 0-1 year 1-6 years 6-12 years 12-18 years >18 years**
(N = 4) (N = 20) (N = 33) (N = 16) (N = 23)
Age (years)* 0.68 (0.21-0.75) 4.10 (2.98-4.97) 8.61 (7.50-10.2) 15 (14.1-17) 25.3 (21.2-33.3)
Weight (kg)* 8.25 (5.03-8.63) 13.7 (12.8-16.7) 28 (23.9-31.7) 54.1(46.9-66.7) 60 (54.2-75)
Z-score -0.28 -0.53 -0.008 0.1 0.17
Height (cm)* 67.5 (58.2-70.7) 95 (91-106) 124(120-133) 160 (150-176) 161(153-171)
Z-score 0.71 -0.48 -0.14 -0.06 -0.63
HC (cm)* 43.2 (39.2-43.9) 48.5 (46.5-49.8) 50 (49.5-53) *** ***
Z-score -0.85 -1.16 -0.68
*Data reflects median and interquartile range. z-score from tables by Hernández et al [29].
**BMI of adult patients is 23.8 (21.6-27.9).
***No data presented since only observations from 2 patients.
HC: Head circumference.
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Wechsler); the mean intelligence quotient was 87 ± 19.
A correlation between the presence of neurological se-
quelae and the type of disease, type of presentation, liver
failure at onset, and ammonia and glutamine levels at
diagnosis was seen (Table 7). Neurological outcome was
worse in patients with CPS1D and ASLD and in those
with neonatal presentation, liver failure at onset and
higher levels of ammonia and glutamine at diagnosis.
Only seven patients (7%) have liver disease, which




OTC 65 44.6 (29, 7m
ASS 21 66.7 (14)
ASL 10 80 (8)




Neonatal 24 75 (18)
Late 64 51.6 (33)
Asymptomatic 13 15.4 (2)
Hepatic failure at diagnosis
Yes 17 82.3 (14)
No 82 45.1 (37)
Laboratory test at diagnosis Median (IQ
Ammonia (μmol/L) 92 400 (200-69
Glutamine (μmol/L) 77 1126 (891-1
Neurological outcome was correlated with the type of UCD disease, type of presentation
The level of statistical significance was obtained using Pearson chi-square* for qualitativhypertransaminasemia or liver hyper-echogenicity. They
are 4 OTCD (3 females) and 3 ASLD patients.Treatment
Dietary treatment was prescribed in 93 patients. Tube
feeding was only prescribed in nine cases (8.91%). The
patient with NAGS deficiency, the patients that under-
went transplantation and two adult cases with OTC



















0) 174 (67.2-270) < 0.001**
672) 917 (751-1196) 0.019**
, presence of liver failure at onset and ammonia and glutamine level at diagnosis.
e variables and the Mann-Whitney U test** for quantitative variables.
Table 9 Pharmacological treatment
Drug Patients (N) Mean ± SD (mg/kg/day)
Sodium phenylbutyrate 50 250 ± 158
Sodium benzoate 4 184 ± 92.3
Combined treatment 10
Sodium phenylbutyrate 250 ± 134
Sodium benzoate 165 ± 80.5
Carglumic acid 1 15
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EAAs in different groups of age is shown and compared
to the WHO/FAO/UN recommendations [32] and the
UK prescriptions for these patients [33]. Protein and
energy intake decreased with age, being slightly below rec-
ommendations in the adult group. 50 patients received
EAA supplements (20-30% of total protein intake).
Fifty-eight patients were receiving arginine supplemen-
tation (2 CPS1D, 29 OTCD, 18 ASSD, and 9 ASLD) at
156 (109-305) mg/kg/day. Doses were significantly higher
in patients with ASSD/ASLD, 165 (120-461) mg/kg/day,
in comparison to patients with OTCD/CPS1D, 136 (80-
250) (p 0.022). Forty-five patients (44 OTCD and 1
CPS1D) were receiving citrulline at doses of 150 (105-199)
mg/kg/day. Twelve of them (11 OTCD and 1 CPS1D)
received supplementation of both amino acids, arginine at
115 (55-224) and citrulline at 201 (57-242) mg/kg/day.
63.4% of the patients (64) received nitrogen scavenging
drugs (68.2% of the symptomatic patients and 30.8% of
the asymptomatic patients), most of them sodium phenyl-
butyrate (PBA) and a much smaller proportion sodium
benzoate or combined treatment (Table 9). The mean age
of the patients in treatment with PBA was 10.9 ± 8.3 years
and that of patients treated with BZ was 24.2 ± 11.6 years
(p < 0.0045). The patient with NAGS deficiency was in
treatment with carglumic acid. Other pharmacological
treatments received by our UCD patients were: carnitine
in 45 patients, vitamin compounds in 25, calcium and
vitamin D in 11, and antiepileptic drugs in 12.
Liver transplantation was performed in 5 patients, 4
with OTCD (3 females) and 1 with citrullinemia. Two of
these patients with OTCD have learning disorders; the
rest have no neurological sequelae. There are no food re-
strictions in their diet and none of the patients receive
treatment with nitrogen scavenging drugs. Two patients
with OTCD receive 50 and 100 mg/kg/day of citrulline,
respectively.
Discussion
We present the data of the first registry of patients with
UCDs in Spain. Since these are rare diseases and thereTable 8 Diet treatment according to age group
Age (N = 93) 0-1y (N = 4)
Total proteins (g/kg/day) 1.86 (0.90-2.95)
Energy (calories) (kcal/kg/day) 102 (92.5-140)
Essential Aminoacids (g/kg/day) 0.39 (0.2-0.5)
Age <6 m 6-12 m
WHO/FAO/UNU* (safe levels proteins) 1.77 1.31
UK practice (N = 45)** Proteins 2 (0.7-2.5) 1.6 (1.2-1.8)
Data reflects median and IQR.
N = number of patients on diet.
y: years; m: months;* Who/FAO/UNU Expert consultation (2007) [32].
**Adam et al. J Hum Nutr Diet 2013; 25: 398-404 [33].are few patients in each center, most publications on
UCDs focus on partial aspects of the disease and only a
few describe the natural history of the disease and the
current situation of the patients. Recently the data of the
American registry [22], a European non-classical UCDs
series [34], and the data of the patients in Finland be-
tween 1998 and 2007 [6] have been published. The com-
parison between these series of patients is difficult,
particularly due to the differences in the percentage of
OTC asymptomatic heterozygous mothers and in the
percentage of cases diagnosed by newborn screening.
Asymptomatic heterozygous females have not been in-
cluded in our study and 87.5% of our patients presented
symptoms at onset, mostly acute encephalopathy.
Data from 104 cases were collected during one year,
11 of which were diagnosed over this period. As in other
UCDs series, the most frequent condition was OTCD
(64. 4%, 61.2% females) followed by ASSD and ASLD;
the remaining conditions were present in a much lower
proportion.
Assuming these were all the cases in Spain in that
period, and according to the population data from the
Spanish Statistical office [35] (46,609,652 inhabitants
and 425,533 newborns), the period prevalence would be
1:448,169 inhabitants and the incidence 1:70,922 new-
borns. The incidence is lower to that found in other epi-
demiological studies, e.g., 1:22.179 in the West Midlands
in the United Kingdom [5], 1: 39.000 in Finland [6], 1:
41.506 in Italy [4], 1:53.717 in Canada [3] and 1:35.000
in USA [7]. This could be due to the fact that the data
was collected for only one year and the age at diagnosis1-10y (N = 47) 11-18y (N = 20) >18y (N = 22)
0.95 (0.7-1.2) 0.84 (0.65-0.94) 0.7 (0.57-0.92)
72 (58-95) 40 (32-43,5) 36 (30-42)
0.3 (0.27-0.43) 0.25 (0.14-0.48) 0.2 (0.11-0.41)
1-10y 11-16y >16y
0.92-1.14 0.84-0.90 0.84-0.87
1.3 (1-1.7) 0.9 (0.7-1.4) 0.8 (0.4-1.2)
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since OTC deficiency, the most frequent of the UCDs, is
not detected by NBS. Furthermore, the expanded NBS is
still not performed in all the regions in Spain. Consider-
ing that in our series more than half of the cases (55.8%)
were diagnosed after 1 year of age, the estimated inci-
dence would be at least double of what we have found.
The median age of our patients at last visit was 9.6 years,
25% of which were over 18 years and 16% were between
12 and 18 years. In the Finnish series [6], the mean age
was 13 years, and in European non-classical UCD series
[34] the mean age was 18 years (50% of adults). This indi-
cates that there is a need to establish adult centers with
specialists for the follow up of this type of patients.
Great heterogeneity was observed regarding the mo-
lecular genetic data. A total of 63 different mutations
were identified in 98 alleles, 18 (18.3%) of them are
newly described in this work (Tables 4 and 5). Six of the
eight new mutations in patients with OTC deficiency
(p.Thr343Arg, p.Glu273del; p.Thr93Ileu, p.Lys88Thr,
p.Ileu85Ser and c.298 + 1G > C) were identified in pa-
tients with late onset and no neurological symptoms at
last visit, meaning these mutations could be related to a
good prognosis, although the gender of the patients (4
females) could have contributed to this good outcome.
Conversely, the new and presumably deleterious mutation,
p.Phe48Leufs*16, was identified in a severe case of a male
with neonatal onset. The most frequent mutation in
OTCD was p.Arg129His identified in 5 patients with good
neurological outcome. This mutation was described for
the first time in 3 of our patients [24]. The second muta-
tion in frequency was p.Arg40His which has already been
described in patients with variable phenotype including
patients without symptoms [36-38].
None of our patients with type 1 citrullinemia had
mutations previously associated with the mild forms of
the condition, p.Trp179Arg, p.Val263Met, or p.Gly362-
Val [39]. Nevertheless, we identified the mutation p.
Arg86Cys and the new p.Thr91Ala in four patients with
a good neurological outcome, two of them detected by
NBS, suggesting these two changes could be related to
good prognosis of the disease.
Regarding argininosuccinic aciduria, from the five new
mutations identified, p.Arg456Gln was detected in one
patient diagnosed by NBS and without neurological
damage at the age of four. The other mutation in this
patient was p.Arg379Gly, previously associated with a
mild phenotype when homozygous [40]. We cannot
know if the good neurological evolution of this patient is
due to the mild effect of the mutations on the protein
function or to the early diagnosis and treatment.
In general, the great genetic heterogeneity in our short
series of ASS and ASL deficient patients defies perform-
ing a realistic genotype phenotype correlation.This is the first study that shows anthropometric data
in a large series of patients with UCDs. The z-score of
the weight and height was in the normal range for
Spanish population in all the age groups, although
some patients were bellow -2SD (Table 6). The Z-score
for the height in the adult group (-0.6) was the lowest,
which could be related to the fact that they are the pa-
tients with a longer follow-up, but also because during
their first years of life they did not benefit from the
treatments and nutritional formulas we have today. In
this study we have not collected data such as essential
fatty acids, vitamins, trace elements, etc., that would in-
form us of the nutritional status of patients, but we
must point out that the levels of albumin are within
normal values (Table 2).
As already stated, it is difficult to compare between
the series regarding the presence of neurological damage
because the inclusion criteria differ and because the es-
tablishment of the expanded NBS in certain countries
has changed the natural history of the disease for some
of these disorders (ASSD, ASLD, and ARG1D), improv-
ing their prognosis [41,42]. In our series, that does not
include asymptomatic heterozygous mothers and only
12.5% of the cases were diagnosed in a pre-symptomatic
state, 52.5% of the cases had neurological complications.
In the American series, in which 48% of the OTC pa-
tients were asymptomatic heterozygous females, 39% of
the patients had psychomotor or intellectual retardation
and 35% learning disorders [22]. In the European non-
classical UCDs series with 49% asymptomatic cases at
diagnosis, 36% had mental retardation or developmental
delay [34]. In all studies the disorder with the worst
neurological prognosis, is ASLD. In the Finnish series,
all ASLD patients that survived had some type of im-
pairment and 30% were epileptic, despite the fact that
some had been diagnosed before birth, had early treat-
ment, and an absence of hyperammonemic episodes [6].
In the European series, 65% of the patients with ASLD
had psychomotor or intellectual retardation, all those
with symptoms at onset, and even three that were diag-
nosed by NBS [34]. In our series, 80% of the patients
with ASL deficiency had neurological damage, even one
that was diagnosed in the presymptomatic state. This is
indicative that there are other factors besides hyperam-
monemia causing neurological damage, e.g., high con-
centrations of argininosuccinic acid in the CNS, low
production of nitric oxide etc. The frequency of neuro-
logical damage in patients with OTC deficiency was
44.6%, similar to those referred in other series [6,34].
Regarding type 1 citrullinemia, in the European non
classical series with 67% of patients diagnosed by NBS,
16% had psychomotor or intellectual retardation [34]. In
our series, neurological damage affected 66% of patients,
probably because 63.6% of our citrullinemia cases were
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NBS. Since the expanded NBS has been recently estab-
lished in our country, these figures might change in the
future. Mild variants of citrullinemia, which may possibly
be without any clinical significance, have been ascertained
in the NBS programs. This is why these programs are be-
ing carefully evaluated and citrullinemia has been ex-
cluded from the screening panel in some European
countries [42].
As in other series, ammonia and glutamine levels at onset
were also related to neurological outcome; 75% of the pa-
tients without sequelae had ammonia levels ≤270 μmol/L.
Thus, to improve neurological prognosis it is necessary to
have early diagnosis and treatment of hyperammonemia.
Treatment of UCDs combines dietary and pharmaco-
logical therapy. In our series, 92% of the cases were under
dietary treatment. A protein restricted diet was used in
the European non-classical UCDs series with 82% of the
symptomatic patients and 14% of the asymptomatic cases
[34], and in the American series with 63% of the total,
which includes the asymptomatic heterozygous mothers
[22]. The studies describing dietary recommendations for
these patients are scarce [11,18,43-45]. The importance of
low-protein diet, sufficient caloric intake and supplements
of EAA, minerals, vitamins and long-chain polyunsatur-
ated fatty acids in order to prevent deficiencies is pointed
out in all the studies. In the European Guidelines [11], re-
cently published, dietary recommendations are based on a
C-D evidence level. The Guidelines suggest following the
FAO/WHO/UNU recommendations for protein and en-
ergy requirements [32], adapting them according to clin-
ical data. They recommend administering 20-30% of the
protein (50% in ARG1 deficiency) in the form of EAA in
those patients with low protein tolerance in order to
maintain growth and metabolic control. During the last
few months, two studies have been published regarding
dietary treatment in clinical practice in the UK [33] and in
other European countries [46] showing that dietary prac-
tices vary widely between European IMD centers, particu-
larly with regard to total protein restriction in early
infancy, EAAs and approach to nutritional support.
The amount of protein consumed by our patients de-
creases with age. It is somewhat lower than in the UK
[33] but similar to other European countries [46] and ac-
cording with the WHO recommendations [32], except in
the adult group in which is slightly lower (Table 8). In
the group of children younger than a year the protein in-
take is in the high normal range, but we have to say that
3 out of 4 of these patients have citrullinemia diagnosed
by NBS, possibly mild forms of the disease. In the rest of
the children the intake of protein is in the low normal
range of the WHO recommendations. There is no pub-
lished data on the caloric intake in large series of patients
with UCD and therefore we cannot make comparisonswith our data, but we can state that our data is in keeping
with that obtained through the WHO recommended for-
mulas. In our study 50% of the patients received EAA sup-
plementation, this accounts approximately for 20-30% of
the total protein intake. In the UK 30% of the patients re-
ceived this supplementation and in the rest of Europe 38%
on average, with notable differences according to country
(100% in Sweden, 64-67% in Germany and Portugal and
24-29% in France, Denmark and Italy). In the USA they
are recommended for all patients, supplying 50% of total
protein intake in infancy, later reducing this percentage to
25% [45]. The advantage of the EAA would be to decrease
the load of ammonia in the urea cycle, since they contain
less nitrogen than natural proteins. Besides, given their
lower content in tryptophan, tyrosine and phenylalanine,
less tryptophan would go to the CNS in situations of
hyperammonemia and the production of serotonin would
decrease. Lastly, the higher content in branch-chained
amino acids would counteract the deficiency of these
amino acids found in patients treated with PBA. There-
fore, the tendency is to use them in a greater number of
patients.
According to the recommendations, arginine and/or
citrulline are used to remove ammonia, taking advantage
of the urea cycle reactions that are not blocked. In prox-
imal defects, such as in OTC or CPS1 deficiencies, ar-
ginine and/or citrulline have been used in 95% (64/67)
of patients, arginine alone in 19 cases, citrulline alone in
33 cases, and both in 12 cases. There are no studies
comparing the efficacy of the two. For distal defects
(ASSD and ASLD) arginine has been used in 87% (27/
31) of the cases in significantly higher doses than those
used for proximal defects.
The medications used in UCDs are nitrogen scaven-
ging drugs, PBA and SB, which remove the ammonia
through alternative routes. In our series, 68% of the
symptomatic cases received nitrogen scavenging drugs,
a percentage similar to the 66% in the American series
[22], and the 72% in the European series [34]. In our
series, as in the American one, PBA was used more fre-
quently (49.5%) than SB (3.96%) or the combined ther-
apy (9.9%). In the American series [22], PBA was used
in 58% of the cases and SB in 8% of the symptomatic
cases. Conversely, in the European series [34], SB was
given to 23% of the patients, PBA to 13%, and both to
16%. Furthermore, in our series the age of the patients
that were given SB was significantly higher than those
to which SB was administered, indicating that the
current tendency is to prescribe PBA.
Surprisingly, many patients in our series are still re-
ceiving carnitine. Its use was advocated by some in the
past, but has proven to be of little benefit in these dis-
orders and not recommended in the last European
guidelines.
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tients registered with UCDs, of which 87% were index-
patients diagnosed due to symptoms. 25% have reached
adulthood and 52% have neurological damage. 92% of
the patients are under nutritional therapy, consisting of
a normocaloric, low-protein diet, supplemented with
EAA in 50% of the cases. 87% of the cases with ASS/
ASL deficiency receive treatment with arginine, and 98%
of the patients with OTC/CPS1 deficiency receive argin-
ine and/or citrulline. 68% of the symptomatic cases are
treated with a nitrogen scavenging drug, mainly sodium
phenylbutyrate. The Z-score of the weight and height of
our patients was normal in all age groups, although
lower than the median in height, our study being the
first to show the anthropometric data in these patients.Conclusions
Expanded registries of rare diseases are indispensable
to help understand the natural history of these patholo-
gies and how they may change over time due to better
diagnostic and therapeutic tools. It also helps under-
stand the pathophysiology of these diseases, as many
genetic or phenotypic data may not be reported indi-
vidually. In our case, we report 18 novel mutations for
various deficiencies.
In order to improve the neurological prognosis of these
patients, the expanded newborn screening should be
extended to the entire country. As well as this, there is a
need for greater diffusion of the knowledge regarding
these diseases to general pediatricians, neurologists and
neonatologists so we can diagnose them in the pre-
symptomatic state or when ammonia is below the levels
that cause irreversible neurological damage.
There is a clear need to incorporate specialists who
treat adults with these diseases in metabolic units, for
the follow up and treatment of patients once they reach
adulthood. Likewise, the integration of dietitians, neuro-
psychologists and social workers in metabolic units are
also required to facilitate the multiple needs these pa-
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